spacer
home > ebr > winter 2003 > capturing recombinant proteins
PUBLICATIONS
European Biopharmaceutical Review

Capturing Recombinant Proteins

Recombinant DNA technologies are widely used in the drug discovery process, not only to produce novel, engineered proteins, but also to generate proteins in the quantities required for downstream research. Purifying these proteins remains a bottleneck. This article looks at a novel method to rapidly isolate structurally and functionally intact histidine-tagged recombinant proteins using superparamagnetic beads.

Recombinant DNA (rDNA) technologies are a cornerstone of the biotechnology industry and have revolutionised approaches to the discovery of new medicines. Pioneered by scientists such as Paul Berg, Stanley Cohen and Herbert Boyer in the early 1970s, rDNA methodologies allow scientists to 'cut and paste' DNA to engineer novel proteins, and to transfer DNA from one organism to another. They also provide the means to generate proteins in the quantities required for downstream studies in drug discovery - from target identification, target validation and screening of compound libraries, to ADME-Tox studies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Beate Rygg Johnsen, Product Manager at Dynal Biotech

Beate Rygg Johnsen is an International Product Manager at Dynal Biotech, Oslo in Norway and is responsible for the company's efforts within the area of proteomics. Beate is driving Dynal Biotech's penetration in drug discovery. She holds a MSc and a Cand Scienct from the University of Oslo, Institute of Biochemistry, and a degree in marketing management from BI, Norwegian School of Management.

spacer
Beate Rygg Johnsen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Trial Supply West Coast Conference 2019

Philadelphia, USA – April 24, 2019. This year’s Clinical Trial Supply West Coast Conference will see leading biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) showcasing its specialist clinical trials expertise in relation to scheduled drugs.
More info >>

White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement